Evidence map›Paper›PMID 40777010›Full record

ArticleFrontiers in immunology2025

Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment.

Dalia Ibrahim, Melanie Grondin, Kristianne Galpin, Sara Asif, Emily Thompson, Sarah Nersesian, John Abou-Hamad, Maryam Echaibi, Galaxia M Rodriguez, Pauline Navals and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dalia IbrahimCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Melanie GrondinCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Kristianne GalpinCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Sara AsifCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Emily ThompsonCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Sarah NersesianCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
John Abou-HamadCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Maryam EchaibiCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Galaxia M RodriguezCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Pauline NavalsDepartment of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON, Canada.
Elizabeth MacdonaldCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Brianna RyanDepartment of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON, Canada.
David P CookCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Jeffrey W KeillorDepartment of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON, Canada.
Barbara C VanderhydenCancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ovarian cancer is the most lethal gynecological malignancy. Deepening our knowledge of the interactions within the tumor microenvironment (TME) is important for discovering new targeted treatment strategies. Transglutaminase 2 (TG2) is a protein implicated in many biological and pathophysiological processes, including promoting tumor progression in ovarian cancer. Its role in disease progression has been studied in ovarian cancer cells; however, its role in the ovarian TME is less understood. Methods: In this study, for the first time, we assessed the therapeutic potential of novel covalent irreversible small molecule TG2 inhibitors in xenograft models of ovarian cancer. We further elucidated the role of TG2 in ovarian cancer cells and syngeneic tumors by immune phenotyping using flow cytometry, RNA sequencing, and immunohistochemistry to characterize the contribution of TG2 in the TME to the metastatic process of ovarian cancer. Results: To investigate the transamidation catalytic and GTP binding activities of TG2 in cancer cells, we used several TG2 inhibitors, some of which decreased invasiveness of human ovarian cancer cell lines in vitro and lengthened survival of the SKOV3 xenograft model. Using the ID8 Discussion: These findings highlight the importance of TG2 in the TME for ovarian cancer metastasis, potentially by activation of humoral immunity and specifically highlight a crucial role for TG2 in modulating B cells to prolong survival in mouse models of ovarian cancer.

Indexed as

Ovarian NeoplasmsProtein Glutamine gamma Glutamyltransferase 2TransglutaminasesTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalFemaleGTP-Binding ProteinsHumansMiceNeoplasm MetastasisXenograft Model Antitumor AssaysGTP-Binding ProteinsProtein Glutamine gamma Glutamyltransferase 2Transglutaminasesimmune modulationmetastasisovarian cancertargeted therapytransglutaminase 2

Identifiers

PMID40777010
PMCPMC12328189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.